A Review on Therapeutic Drug Monitoring in Pediatric Oncology

Zama Muqeem; Hafsa Zaheer; Mohd Naseer Ullah; Shaik Nawaz

doi:10.61280/tjpls.v13i2.269

Zama Muqeem Department of Pharmacy Practice, Deccan School of Pharmacy, Hyderabad, India
Hafsa Zaheer Department of Pharmacy Practice, Deccan School of Pharmacy, Hyderabad, India
Mohd Naseer Ullah Department of Pharmacy Practice, Deccan School of Pharmacy, Hyderabad, India
Shaik Nawaz Department of Pharmacy Practice, Deccan School of Pharmacy, Hyderabad, India

DOI: https://doi.org/10.61280/tjpls.v13i2.269

Keywords:

Therapeutic drug monitoring, Pediatric, Oncology, Chemotherapy, Pharmacokinetic, Genetic Factors

Abstract

Therapeutic drug monitoring (TDM) is advised to guarantee children's safe and efficient dosage. The objective of the study was to create and assess an external population pharmacokinetic, pathophysiological, and pharmacological underpinning for TDM in pediatric oncology. This reflects both organ-specific diseases and common pediatric cases. Methotrexate, busulfan, and asparaginase are important medications under observation. Since children's metabolisms differ, TDM helps modify the course of treatment. Finger pricks are important tactics for decreasing blood loss and predicting drug behavior in various age groups. Therapeutic Drug Monitoring in pediatric oncology supports individualized chemotherapy through analysis of pharmacokinetic differences and genetic factors.

Downloads

Download data is not yet available.

References

Coggins S.A, Wade K.C, Downes K.J. Advances in pediatric therapeutic drug monitoring. Pediatrics. 2026;157(1):e2025073013. https://doi.org/10.1542/peds.2025-073013

Simeoli R, Dorlo TPC, Hanff LM, Huitema ADR, Dreesen E. Therapeutic drug monitoring: a useful tool for pediatric pharmacology applied to routine clinical practice.2022 May 24;13:931843. doi: 10.3389/fphar.2022.931843

Janssen JM, Dorlo TPC, Steeghs N, et al. Pharmacokinetic targets for therapeutic drug monitoring of small molecule kinase inhibitors in pediatric oncology. Clin Pharmacol Ther. 05 February 2020 https://doi.org/10.1002/cpt.1808Digital Object Identifier (DOI)

Hämmerle S, Ernst J, Steiner R, et al. Significance of busulfan administration route including therapeutic drug monitoring in the conditioning regimen of pediatric patients prior to hematopoietic stem cell transplantation. J Cancer Res Clin Oncol.2025 Apr 4;151(4):132. doi: 10.1007/s00432-025-06179-w

Alomari N, Kurdi A, Alghamdi M, et al. Therapeutic drug monitoring of busulfan in pediatric patients: a 5-year observational study. BMC Pharmacol Toxicol. (2025) 26:175. https://doi.org/10.1186/s40360-025-01015-w

Strawn JR, Poweleit EA, Uppugunduri CRS, Ramsey LB. Pediatric therapeutic drug monitoring for selective serotonin reuptake inhibitors. Front Pharmacol. 2021 Oct 1;12:749692. doi: 10.3389/fphar.2021.749692

Ghosh M, Debnath S, Bhat GM, Bairwa S, Rajan R. Small-cell lung carcinoma in an 8-year-old boy: a rare case report with review of literature. Indian Journal of Medical and Paediatric Oncology. 2025;46(03):337–341. https://www.thieme connect.com/products/ejournals/pdf/10.1055/s-0044-1795092.pdf

Khan A.U, Yaseen M, Reddy U.N. The neuroblastoma: A case report and review. 5(4):146-148, 2019. | https://doi.org/10.18231/j.ijmpo.2019.032

Wilms tumor: A case report with typical clinical and radiologic features in a 3-year-old male https://pmc.ncbi.nlm.nih.gov/articles/PMC10023853/

A rare case of peripheral T-cell lymphoma in 1-year-old child https://pmc.ncbi.nlm.nih.gov/articles/PMC3343252/

Neville HL, Hogan AR, Zhuge Y, et al. Incidence and outcomes of malignant pediatric lung neoplasms. J Surg Res. 2009;156(2):224-230.

Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors. J Thorac Oncol. 2015;10(9):1243-1260 https://www.researchgate.net/publication/380292605

Kumari K, Jha AM. Pediatric brain tumor classification and epidemiology. Int J Trends OncoSci. 2024;2(3):14-22. https://www.researchgate.net/publication/382410063

Bustamante RH, Romero W. Gastric adenocarcinoma in childhood: a case report and literature review. Cir Pediatric. 2021;34:151-155.

Subbiah V, Varadhachary G, Herzog C, Huh W. Gastric adenocarcinoma in children and adolescents. Pediatr Blood Cancer.24 January 2011 https://doi.org/10.1002/pbc.23051

Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility and management implications. Lancet Oncol. 2015;Familial gastric cancer: genetic susceptibility, pathology, and implications for management - The Lancet Oncology.

Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: Updated consensus guidelines. J Med Genet. 2010; doi:10.1136/jmg.2009.074237

Cam S, et al. Risk of gastric cancer in children with Helicobacter pylori infection. Asian Pac J Cancer Prev. 2014;15:9905-9908. https://www.researchgate.net/publication/274089723

Agarwal S. Pediatric Cancers: Insights and Novel Therapeutic Approaches. Cancers (Basel). 2023 Jul 8;15(14):3537. Doi:10.3390/cancers15143537

Haung J, Chan S.C, Ngai C.H, Lok V, Zhang L, Prisno III D.E.L, Xu W, Zheng Z.J, Elcarte E, Withers M, Wong M.C.S, NCD, APRU. Global incidence, mortality and temporal trends of cancer in children: A joinpoint regression analysis. Cancer Med. 2022 Jul 13;12(2):1903–1911. Doi:10.1002/cam4.5009

Smita et al. Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices. Frontiers in Oncology. 2022. https://www.frontiersin.org/articles/10.3389/fonc.2022.1015200/full

Alomari N, Kurdi A, Alghamdi M, et al. Therapeutic drug monitoring of busulfan in pediatric patients: A 5-year observational study. BMC Pharmacology and Toxicology. 2025. https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-025-01015-w

Inoue C, Yamamoto T, Miyata H, Suzuki H, Takada T. Elevation of tacrolimus concentration after administration of methotrexate for treatment of graft-versus-host disease in pediatric patients receiving allogeneic hematopoietic stem cell transplantation. J Pharm Health Care Sci. 2023;9:38. https://jphcs.biomedcentral.com/articles/10.1186/s40780-023-00306-w

Skolnik JM, Hall D, Barkauskas DA, Moorthy G, Larson TR, Fox E, et al. Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children’s Oncology Group Study ADVL06B1. Cancer Chemother Pharmacol. 2021;88(2):359–365. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653953/

Besora S, Garcilazo-Reyes Y, Velasco R. Methotrexate-induced neurotoxicity in oncology: Current issues for a classic drug. Volume 473, 15 June 2025, 123514.https://doi.org/10.1016/j.jns.2025.123514

Alomari N, Kurdi A, Alghamdi M, Alhussaini W, Ezzeldeen G, Alharbi E, Aldhahri A, Islam I, Essa M. Therapeutic drug monitoring of busulfan in pediatric patients: a 5-year observational study. BMC Pharmacol Toxicol. 2025 Oct 28;26:175. Doi: 10.1186/s40360-025-01015-w

Li W, Wen C, Ye B, et al. Targeted drug monitoring in oncology for personalized treatment with next-generation analytics. Discover Oncology. 2025;16:XX. Discover Oncology (Springer Nature). 2025.

https://link.springer.com/journal/12672